MARKET

GILD

GILD

Gilead Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

63.09
-0.31
-0.49%
After Hours: 62.76 -0.33 -0.52% 19:59 09/23 EDT
OPEN
63.51
PREV CLOSE
63.40
HIGH
64.08
LOW
63.00
VOLUME
8.52M
TURNOVER
--
52 WEEK HIGH
85.97
52 WEEK LOW
60.89
MARKET CAP
79.10B
P/E (TTM)
-260.0577
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Gilead Settles US Kickback Allegations For $97M
Gilead Sciences, Inc (NASDAQ: GILD) has agreed to pay $97 million to settle allegations that it illegally paid for Medicare co-pays for its own pulmonary arterial hypertension drug Letairis through a charitable entity.
Benzinga · 1h ago
Gilead sciences prices $7.25B of notes in 7 tranches
Gilead Sciences (GILD) prices aggregate senior unsecured notes of $7.25B.Closing date is September 30. Net proceeds will be used to finance a portion of the cash consideration payable in connection
Seekingalpha · 1h ago
Gilead Sciences Prices $7.25 Billion of Senior Unsecured Notes
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $7.25 billion, in an underwritten, registered public offering, consisting of seven tranches:
Business Wire · 3h ago
Gilead to pay $97 million to settle U.S. kickback probe
Gilead Sciences Inc has agreed to pay $97 million to resolve U.S. government claims it used a purportedly independent charity to pay illegal kickbacks to cover Medicare patients' out-of-pocket costs for its pulmonary arterial hypertension drug Letairis. The U.S. Department of Justice said on Wednesday
Reuters · 3h ago
Gilead to pay $97M to settle violations of False Claims Act related to Letairis copays
Gilead Sciences ([[GILD]] -0.5%) has agreed to pay $97M to settle federal allegations that it violated the False Claims Act by illegally using a foundation as a conduit to fund
Seekingalpha · 9h ago
Gilead To Sell $7.25B Of Bonds To Fund Immunomedics Deal
- Bloomberg
Bloomberg · 11h ago
Gilead Sciences, Inc. -- Moody's assigns A3 rating to Gilead's sr. notes; negative outlook
Moody's · 11h ago
UK to host first human challenge studies for COVID-19 vaccines
The Financial Times reports that the UK will host the world's first human COVID-19 challenge trials, in which healthy volunteers are deliberately infected with coronavirus, in order to evaluate the
Seekingalpha · 15h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GILD. Analyze the recent business situations of Gilead Sciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 29 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GILD stock price target is 79.08 with a high estimate of 105.00 and a low estimate of 62.00.
EPS
Institutional Holdings
Institutions: 2.18K
Institutional Holdings: 1.05B
% Owned: 83.78%
Shares Outstanding: 1.25B
TypeInstitutionsShares
Increased
613
82.06M
New
304
-7.36M
Decreased
668
85.47M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Chief Executive Officer/Director
Daniel O'Day
Chief Financial Officer/Executive Vice President
Andrew Dickinson
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Brett Pletcher
Executive Vice President/Director of Human Resources
Katie Watson
Executive Vice President/Director of Human Resources
Jyoti Mehra
Senior Vice President
Linda Higgins
Senior Vice President
Michael Quigley
Other
Johanna Mercier
Other
Merdad Parsey
Lead Director/Independent Director
Kevin Lofton
Director
Javier Rodriguez
Independent Director
Jacqueline Barton
Independent Director
Sandra Horning
Independent Director
Kelly Kramer
Independent Director
Harish Manwani
Independent Director
Richard Whitley
Independent Director
Per Wold-Olsen
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
07/30/2020
Dividend USD 0.68
09/14/2020
04/29/2020
Dividend USD 0.68
06/11/2020
02/03/2020
Dividend USD 0.68
03/12/2020
10/23/2019
Dividend USD 0.63
12/12/2019
07/29/2019
Dividend USD 0.63
09/12/2019
05/01/2019
Dividend USD 0.63
06/13/2019
02/01/2019
Dividend USD 0.63
03/14/2019
10/24/2018
Dividend USD 0.57
12/13/2018
07/24/2018
Dividend USD 0.57
09/13/2018
04/30/2018
Dividend USD 0.57
06/14/2018
02/05/2018
Dividend USD 0.57
03/15/2018
10/25/2017
Dividend USD 0.52
12/14/2017
07/25/2017
Dividend USD 0.52
09/14/2017
05/01/2017
Dividend USD 0.52
06/14/2017
02/06/2017
Dividend USD 0.52
03/14/2017
10/31/2016
Dividend USD 0.47
12/13/2016
07/22/2016
Dividend USD 0.47
09/14/2016
04/27/2016
Dividend USD 0.47
06/14/2016
02/02/2016
Dividend USD 0.43
03/14/2016
10/26/2015
Dividend USD 0.43
12/14/2015
07/23/2015
Dividend USD 0.43
09/14/2015
04/24/2015
Dividend USD 0.43
06/12/2015
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GILD
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Gilead Sciences, Inc. stock information, including NASDAQ:GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.